AI on a GMP site rarely fails because the model is weak. It fails at a specific step in a specific job: a visual inspection model that looks accurate overall but misses glass particles, a camera swap treated as "like for like" with no retest, a soft sensor placed in the control strategy with no independent check, a deviation summary pasted into the record without anyone checking it against the lab results, or an AI feature a SaaS supplier switched on in the last release. This course teaches those jobs one at a time. Each module follows a named role at a fictional US sterile-injectables and biologics site through the task as it is done today, where AI helps and where it must not, the data and systems actually involved (inspection machines, historians, PAT data managers, LIMS, CDS, MES/eBR and eQMS), the product categories and vendors used for that task as of October 2026, the controls that apply to that exact task, how to measure success, and a hands-on exercise with synthetic data for fictional products such as "Examplol 10 mg/mL injection" and "mAb-X".
US rules set the decision boundary throughout: 21 CFR 211.22, 211.68, 211.100, 211.110, 211.180(e), 211.188 and 211.192, 21 CFR Part 11, FDA's April 2026 warning letter citing inappropriate use of AI to write specifications and master records, FDA's January 2025 draft guidances on AI credibility for drug regulatory decision-making and on complying with 211.110, the 2011 Process Validation guidance, the 2018 Data Integrity Q&A, ICH Q9(R1), Q10, Q13, Q2(R2) and Q14, and ISPE GAMP 5 Second Edition with the 2025 GAMP Guide: Artificial Intelligence. FDA's 2025 Computer Software Assurance guidance is taught as device guidance applied to drug systems by analogy only. EU GMP Annex 1 appears because it binds sites that supply the EU market. The July 2025 consultation drafts of EU GMP Annex 22 "Artificial Intelligence" and the revised Annex 11 bind no one; they are taught, labeled as drafts, as signals of where EU and PIC/S expectations are heading, and Annex 22's scope is under revision. Vendor products are named to show the tool categories in use, not as endorsements, and no vendor performance claims are taught as fact. This course is educational, not legal or regulatory advice; leaders take hls-530.